Autoimmune disease induced by dendritic cell immunization against leukemia

Leukemia Research

Volumn 23, Issue 6, 1999, Pages 549-557

  Roskrow, Marie A ^a   Dilloo, Dagmar ^a   Suzuki, Nobuhiro ^a   Zhong, Wanyung ^a   Rooney, Cliona M ^a,b   Brenner, Malcolm K ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Autoimmune disease; Dendritic cells; Leukemia; Tumor vaccine

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 39; INTERLEUKIN 2; TUMOR VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BLOOD DYSCRASIA; CACHEXIA; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; FIBROBLAST; GRAFT VERSUS HOST REACTION; HEPATOSPLENOMEGALY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; LEUKEMIA CELL LINE; LYMPHATIC LEUKEMIA; LYMPHOBLASTOID CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR NECROSIS; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD40; ANTIGENS, NEOPLASM; AUTOIMMUNE DISEASES; CELLS, CULTURED; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C;

EID: 0033058650     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00045-4     Document Type: Article

References (60)

1. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:1991;271.
2. Hsu F., Benike C., Fagnoni F., Lines T.M., Czerwinski D., Taidi B. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:1996;52.
3. Murphy G., Tjoa B., Ragde H., Kenny G., Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 29:1996;371.
4. Gong J., Chen D., Kashiwaba M., Kufe D. Induction of antitumor acitvity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:1997;558.
5. Henderson R.A., Nimgaonkar M.T., Watkins S.C., Robbins P.D., Ball E.D., Finn O.J. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res. 56:1996;3763.
6. van-Elsas A., van-der-Burg S.H., van-der-Minne C.F., Gorghi M., Mourer J.S., Melief C.J. et al. Peptide-pulsed dedritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from Melan-A/MART-1 self antigen. Eur. J. Immunol. 26:1996;1683.
7. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T., Falo L.D.J. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:1996;283.
8. Henderson R.A., Finn O.J. Human tumor antigens are ready to fly. Adv. Immunol. 62:1996;217.
9. Boon T., van Der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:1996;725.
10. Paglia P., Chiondoni C., Rodolfo M., Colombo M.P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:1996;317.
11. Boczkowski D., Nair S.K., Synder D., Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:1996;645.
12. Alderson M.R., Armitage R.J., Tough T.W., Strockbine L., Fanslow W.C., Spriggs M.K. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J. Exp. Med. 178:1993;669.
13. Freudenthal P.S., Steinman R.M. The distinct surface of human blood dendritic cells as observed after an improved isolation method. Proc. Natl. Acad. Sci. USA. 87:1990;7698.
14. Caux C., Massacrier C., Vanbervliet B., Dubois B., van Kooten C., Durand I., Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1994;1263.
15. Cayabyab M., Phillips J.H., Lanier L. L. CD40 preferentially costimulates activation of CD4+ T lymphocytes. J. Immunol. 152:1994;1523.
16. Wagner D.H., Stout R.D., Suttles J. Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur. J. Immunol. 24:1994;3148.
17. Fanslow W.C., Clifford K.N., Seaman M., Alderson M.R., Spriggs M.K., Armitage R.J. et al. Recombinant CD40 ligand exerts potent biologic effects on T cells. J. Immunol. 152:1994;4262.
18. Armitage R.J., Tough T.W., Macduff B.M., Fanslow W.C., Spriggs M.K., Ramsdell F. et al. CD40 ligand is a T cell growth factor. Eur. J. Immunol. 23:1993;2326.
19. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell. 76:1994;241.
20. Dilloo D., Brown M., Roskrow M., Zhong W., Holden W., Holladay M. et al. CD40 ligand acts as a co-stimulator molecule for the generation of an anti-tumor immune response. Blood. 90:1997;1927.
21. Kim K.J., Kanellopoulos-Langevin C., Verwin R.M., Sachs D.H., Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122:1979;549.
22. Patek P.Q., Collins J.L., Cohn M. Transformed cell lines susceptible or resist to in vivo surveillance against tumorigenesis. Nature. 276:1978;510.
23. Bender M.A., Palmer T.D., Gelinas R.E., Miller A.D. Evidence that the packaging signal of Moloney, Murine Leukemia Virus extends into the gag region. J. Virol. 61:1987;1639.
24. Brenner M.K., Rill D.R., Holladay M.S., Heslop H.E., Moen R.C., Buschle M. et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 342:1993;1134.
25. Brenner M.K., Furman W.L., Santana V.M., Bowman L., Meyer W. Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma. Hum. Gene. Ther. 3:1992;665.
26. Coleclough C. Cell-free expression of large collections of cDNA clones using positive-selection I phage vectors. Meth. Enzymol. 217:1993;152.
27. Pear W.S., Nolan G.P., Scott M.L., Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA. 90:1993;8392.
28. Dialynas D.P., Quan Z.S., Wall K.A., Pierres A., Quintans J., Loken M.R. et al. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5; similarity of L3T4 molecule. J. Immunol. 131:1983;2445.
29. Sarmiento M., Glasebrook A.L., Fitch F.W. IgG of IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing LYT 2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol. 125:1980;2665.
30. Fulcher D.A., Lyons A.B., Korn S.L., Cook M.C., Koleda C., Parish C. et al. The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J. Exp. Med. 183:1996;2313.
31. Ferrara J.L.M., Deeg H.G. Graft-versus-host disease. N. Engl. J. Med. 324:1991;667.
32. Korngold R. Biology of graft-versus-host disease. Am. J. Ped. Hem/Onc. 15:1993;18.
33. Truitt R.L., Atasoylu A.A. Contribution of CD4+and CD8+T cells to graft-versus-host-disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transpl. 8:1991;51.
34. Maldonado M.A., Eisenberg R.A., Roper E., Cohen P.L., Kotzin B.L. Greatly reduced lymphoproliferation in lrp mice lacking major histocompatibility complex class I. J. Exp. Med. 181:1995;41.
35. Grabbe S.S., Beissert S., Schwartz T., Granstein R.D. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy. Immunol. Today. 16:1995;117.
36. Tjoa B., Boynton A., Kenny G., Ragde H., Misrock S.L., Murphy G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate. 28:1996;65.
37. Marrack P., Hugo P., McCormack J., Kappler J. Death and T cells. Immunol. Rev. 133:1993;119.
38. Pardoll D., Darreara A. Thymic Selection. Curr. Opin. Immunol. 4:1992;162.
39. Scollay R.G., Butcher E.C., Weissman I.L. Thymus cell migration: Quantitative aspects of cellular traffic from the thymus to the periphery in mice. Eur. J. Immunol. 10:1980;210.
40. Tough D.F., Spren J. Turnover of naive-and memory-phenotype T cells. J. Exp. Med. 179:1994;1127.
41. Cyster J.G., Hartley S.B., Goodnow C.C. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature. 371:1994;389.
42. Kroemer G., Hirsch F., Gonzalez-Garcia A., Martinez C. Differential involvement of Th1 and Th2 cytokines in autoimmune disease. Autoimmunity. 24:1996;25.
43. Harding C.V., Song R. Phagocytic processing of exogenous particulate antigen by macrophages for presentation by class I MHC molecules. J. Immunol. 153:1994;4925.
44. Grant E.P., Rock K.L. MHC class I restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J. Immunol. 148:1992;13.
45. Reis E., Sousa C., Germain R.N. Major histocompatibility complex class I presentation peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med. 182:1994;841.
46. Bevan M.J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143:1976;1283.
47. Kurts C., Heath W.R., Carbone F.R., Allison J., Miller J.F.A.P., Kosaka H. Constitutive class I-restricted exogenous presentation of self-antigens in vivo. J. Exp. Med. 184:1996;923.
48. Den Haan J.M.M., Sherman N.E., Blokland E., Huczko E., Koning F., Dijfhout J.W. et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 268:1995;1476.
49. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzaveccia A., Albert G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity:T-T help via APC activation. J. Exp. Med. 184:1996;747.
50. Koch F., Stanzl U., Jennewein P., Janke K., Heufler C., Kampgen E. et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class Il and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:1996;741.
51. Ranheim E.A., Kipps T.J. Elevated expression of CD80 (B7.1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. Arthritis Rheum. 37:1994;1637.
52. Tandon N., Metcalfe R., Barnett D., Weetman A. Expression of the costimulatory molecule B7/BB1 antigen in autoimmune thyroid disease. Quart. J. Med. 87:1994;231.
53. Sharpe A.H. Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Curr. Opin. Immunol. 7:1995;389.
54. Guerder S., Picarella D.E., Linsley P., Flavell R.A. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor (leads to autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. USA. 91:1994;5138.
55. Early G.S., Zhao W., Burns C.M. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black×New Zealand white mice. Response correlates with the absence of an anti-antibody response. J. Immunol. 157:1996;3159.
56. Kalled S.L., Cutler A.H., Datta S.K., Thomas D.W. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J. Immunol. 160:1998;2158.
57. Durie F.H., Fava R.A., Foy T.M., Aruffo A., Ledbetter J.A., Noelle R.J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 261:1993;1328.
58. Gerrits K., Laman J.D., Noelle R.J., Aruffo A., Ledbetter J.A., Boersma W.J. et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA. 19:1996;2499.
59. Molldrem J., Dermime S., Parker K., Jiang Y., Mavroudis Z,D., Hensel N. et al. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from Proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 88:1996;2450.
60. Celis E., Tsai V., Crimi C., Demars R., Wentworth P.A., Chesnut R.W. et al. Induction of anti-tumor cytotoxic T lymphocytes in normal-humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA. 91:1994;2105.